JP2015521632A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521632A5
JP2015521632A5 JP2015518732A JP2015518732A JP2015521632A5 JP 2015521632 A5 JP2015521632 A5 JP 2015521632A5 JP 2015518732 A JP2015518732 A JP 2015518732A JP 2015518732 A JP2015518732 A JP 2015518732A JP 2015521632 A5 JP2015521632 A5 JP 2015521632A5
Authority
JP
Japan
Prior art keywords
apc
use according
skin
psoriasis
motomeko
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015518732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521632A (ja
JP6273272B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2013/000729 external-priority patent/WO2014005183A1/en
Publication of JP2015521632A publication Critical patent/JP2015521632A/ja
Publication of JP2015521632A5 publication Critical patent/JP2015521632A5/ja
Application granted granted Critical
Publication of JP6273272B2 publication Critical patent/JP6273272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015518732A 2012-07-04 2013-07-04 炎症性皮膚障害の治療 Active JP6273272B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902874A AU2012902874A0 (en) 2012-07-04 Treatment of inflammatory skin disorders
AU2012902874 2012-07-04
PCT/AU2013/000729 WO2014005183A1 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders

Publications (3)

Publication Number Publication Date
JP2015521632A JP2015521632A (ja) 2015-07-30
JP2015521632A5 true JP2015521632A5 (https=) 2016-08-25
JP6273272B2 JP6273272B2 (ja) 2018-01-31

Family

ID=49881162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518732A Active JP6273272B2 (ja) 2012-07-04 2013-07-04 炎症性皮膚障害の治療

Country Status (12)

Country Link
US (3) US20150150954A1 (https=)
EP (1) EP2869833B1 (https=)
JP (1) JP6273272B2 (https=)
KR (1) KR102068010B1 (https=)
CN (1) CN104394883B (https=)
AU (1) AU2013286812B2 (https=)
BR (1) BR112015000051A2 (https=)
CA (1) CA2877745C (https=)
ES (1) ES2676422T3 (https=)
IN (1) IN2014DN11181A (https=)
RU (1) RU2662564C2 (https=)
WO (1) WO2014005183A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013286812B2 (en) * 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
PL3131572T3 (pl) * 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
PT3137102T (pt) * 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
EP3527570A4 (en) 2016-10-14 2020-04-15 Jiangsu Hengrui Medicine Co., Ltd. FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞(msc)の調製物を含む助剤、ならびにその使用方法
US20210268062A1 (en) * 2018-06-28 2021-09-02 Novapep Pty Ltd Inflammatory skin disorder treatment
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
KR20210121039A (ko) * 2018-12-26 2021-10-07 다이렉트 바이오로직스 엘엘씨 피부 및 모발 장애를 치료하기 위한 방법 및 조성물
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインc調製物及びその製法
WO1995030429A1 (en) 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
UA55448C2 (uk) 1997-04-28 2003-04-15 Елі Ліллі Енд Компані Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
WO2001056532A2 (en) 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
ES2242740T3 (es) * 2000-03-28 2005-11-16 Eli Lilly And Company Proteina c activada para el tratamiento de pancreatitis.
JP4071105B2 (ja) 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインcまたは活性化プロテインc様分子
JP4351041B2 (ja) * 2001-06-13 2009-10-28 ザ・ユニバーシティ・オブ・シドニー 傷治癒のための処置および組成物
WO2004041296A2 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
DE50304744D1 (de) 2003-04-28 2006-10-05 Biofrontera Bioscience Gmbh Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
WO2005007820A2 (en) 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
EP1841442A4 (en) * 2005-01-07 2009-12-09 Northern Sydney And Central Co TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
ZA200800251B (en) 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
EP1910385B1 (en) * 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
CA2668187A1 (en) 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) * 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
US8912142B2 (en) * 2009-04-01 2014-12-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Method of regulating proliferation and differentiation of keratinocyes
CN101912450A (zh) * 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
AU2013286812B2 (en) * 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
PT3137102T (pt) * 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
PL3131572T3 (pl) * 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
US20210268062A1 (en) * 2018-06-28 2021-09-02 Novapep Pty Ltd Inflammatory skin disorder treatment

Similar Documents

Publication Publication Date Title
JP2015521632A5 (https=)
US10695287B2 (en) AMPK agonist topical medication for the treatment of certain specific medical conditions, methods of use thereof and wound dressing employing the same
WO2010070675A8 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
RU2015103510A (ru) Лечение воспалительных заболеваний кожи
MX2010000927A (es) Uso de analogos y derivados de la vitamina k para el tratamiento de transtornos y condiciones de enfermedad en humanos.
CA3006294A1 (en) Combinations of rapamycin and metformin for the treatment of joint and skin diseases
WO2015066647A3 (en) Ionic liquids for transdermal drug delivery
BR112015005339A8 (pt) uso de óleo de semente de fruta milagrosa como um ingrediente ativo
EA201170876A1 (ru) Применение способной к вспениванию композиции, по существу, не содержащей фармацевтически активные ингредиенты, для лечения кожи человека
EP4552650A3 (en) Methods and compositions for treatment of skin
WO2009022338A3 (en) Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
RU2007118663A (ru) Способ применения адапалена при поддерживающей терапии угревой сыпи
JP2020525460A5 (https=)
RU2011148355A (ru) Применение аллопуринола для ладонно-родошвенного синдрома
BR112014030777A2 (pt) método e composição para aliviar sintomas de tumor
CA2566776A1 (en) Method for ameliorating an inflammatory skin condition
WO2017129108A1 (zh) 一种用于治疗皮肤病的硅凝胶
JP2014532694A5 (https=)
WO2014070696A3 (en) Treatment of chronic dermal inflammatory with norketotifen
BRPI0417116A (pt) usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação
BR112014005966A2 (pt) composições para o tratamento de úlceras periféricas de várias origens
WO2016063265A3 (pt) Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos
BRPI0415225A (pt) composições tópicas compreendendo telmesteìna para o tratamento de distúrbios dermatológicos
AU2017259411A1 (en) Treating activated dermal conditions with agents that target energy metabolism